ADXS fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded in November 2017 and is headquartered in Monmouth Junction, NJ.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
ADXS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company